When I emailed RH yesterday to ask him to post the Q2 BIO 2016 slides, he also responded

"...(T)he company is very focused on working with License partners and companies that have entered into License Research agreements. However, that data remains confidential. We are working on our LSD program with Scarpa and are in the midst of a dosing study, but that data is not out yet. As for our oncology program we are in the process of preparing for a phase zero study, but the timing for that is predicated on material prep and patient availability."

So based on this, sounds like 1) BIO 2016 was the better venue for continuing to network and bring in new licensing partners; 2) LSD dosing study with Scarpa is still ongoiong; and 3) start of some human work is imminent. According to Wikipedia, the goals of Phase 0 studies are "Pharmacodynamics and Pharmacokinetics particularly oral bioavailability and half-life of the drug." RH said that IND filing is not necessary for Phase 0.

BearDownAZ